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In the basal ganglia circuitry, the striatum is a highly complex structure coordinating motor
and cognitive functions and it is severely affected in Huntington’s disease (HD) patients.
Transplantation of fetal ganglionic eminence (GE) derived precursor cells aims to restore
neural circuitry in the degenerated striatum of HD patients. Pre-clinical transplantation
in genetic and lesion HD animal models has increased our knowledge of graft vs. host
interactions, and clinical studies have been shown to successfully reduce motor and
cognitive effects caused by the disease. Investigating the molecular mechanisms of striatal
neurogenesis is a key research target, since novel strategies aim on generating striatal
neurons by differentiating embryonic stem cells or by reprogramming somatic cells as
alternative cell source for neural transplantation.
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ANATOMY OF THE ADULT STRIATUM
The striatum, sometimes referred as Neostriatum or Corpus
Striatum, is located at the ventral part of the telencephalon where
it coordinates cognitive and motor impulses between basal gan-
glia and cerebral cortex. The term striatum (Latin striatus =
striped) describes two brain nuclei sharing the same ontogenic
origin in the telencephalic primordium: the putamen (Latin puta-
men = stone in a fruit) and caudate nucleus (Latin cauda = tail).
Located in the ventral telencephalon adjacent to the lateral ven-
tricles, the central round putamen is ensheathed by the C-shaped
caudate nucleus at its dorsal part. The ventrorostral part where
the head of the caudate nucleus and the anterior putamen are
fused is referred as Nucleus accumbens. Due to its connectivity
within the mesolimbic pathway, the Nucleus accumbens is rather
considered as interface between basal ganglia and limbic system.
In the human brain, putamen and caudate nucleus appear as
two individual structures separated by the dense fiber tracts of
the internal capsule, whereas in the rodent brain the separation
of caudate nucleus and putamen is less evident because fibers
of the internal capsule appear more distributed throughout the
striatum.
NEURONAL CELL TYPES AND PROJECTIONS OF THE STRIATUM
The striatum consists of about 96% projection neurons. Striatal
projection neurons have a medium-sized soma (∼10–15μm in
diameter), a long extending axon and a number of dendrites with
densely packed spines which is why they are referred as medium
spiny neurons (MSN). Medium spiny projection neurons release
the inhibitory neurotransmitter γ-amino butyric acid (GABA),
as well as different neuropeptide transmitters such as Enkephalin,
Dynorphin, and Substance P (Kawaguchi et al., 1995; Kawaguchi,
1997).
Based on their projection sites, MSNs can be divided into two
populations. The first population projects directly from the stria-
tum to the substantia nigra pars reticulata (SNr) and the internal
segment of the globus pallidus (GPi). This projection is referred
as the direct pathway, since it directly projects the basal ganglia
output nuclei. The second population also projects to the SNr
and GPi, but indirectly via several intermediate relays in the exter-
nal part of the globus pallidus (GPe) and the subthalamic nucleus
and is referred as the indirect pathway. Neurons projecting in the
direct or indirect pathway are equal in proportion among striatal
neurons. Interestingly, neurons of both populations can be distin-
guished based on their peptide transmitters on the one hand and
their dopamine receptors on the other hand (LeMoine and Bloch,
1995; Durieux et al., 2011). Neurons of the direct pathway release
Substance P and Dynorphin as co-transmitters and express type 1
dopamine receptors predominantly. Upon dopamine release from
the substantia nigra pars compacta (SNc), neurons that express
this receptor type become activated and release GABA to the SNr.
Striatal projection neurons of the indirect pathway express type 2
dopamine receptors and release Enkephalin as a co-transmitter.
Type 2 dopamine receptor positive neurons become inhibited
once dopamine is released from the SNc. Thus, dopamine has dif-
ferent effects on striatal neurons: depending on their projection
sites, MSNs become either activated or inhibited by the release of
dopamine.
Furthermore, about 4% of the striatal neurons are aspiny
interneurons, with about 3% cholinergic interneurons, and 1%
GABAergic interneurons. Among the GABAergic interneurons,
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three populations can be distinguished based on the neuropep-
tides Somatostatin, Calretinin, and Parvalbumin which serve
as co-transmitter. In addition to co-transmitter phenotypes,
GABAergic interneurons can be distinguished by their firing
behavior. Parvalbumin expressing interneurons are fast spiking,
whereas Somatostatin positive interneurons are characterized by
low threshold calcium spikes (LTS). For Calretinin positive stri-
atal interneurons a persistent and low-threshold spiking (PLTS)
has been postulated (Tepper and Bolam, 2004). Besides co-
transmitters and firing behavior, striatal projection neurons as
well as GABAergic and cholinergic interneurons can be dis-
tinguished by their nuclear morphology and heterochromatin
distribution using TO-PRO3 staining (Matamales et al., 2009).
STRIATAL AFFERENTS
In addition to their target projection, striatal neurons can also
be classified by the specific inputs they receive. MSN receive
dopaminergic input from the SNc. Furthermore, MSN are also
innervated by cortical and thalamic neurons (Gerfen, 1989, 1992).
Excitatory glutamatergic innervation from the cortex to the stria-
tum occurs mainly from limbic cortical areas in layer IV and the
premotor cortex in layer V. Dopaminergic innervation of striatal
neurons is established earlier in development than cortical and
thalamic innervation. The cortical input from layer IV and layer
V results in a morphological pattern that is referred as striosome-
matrix subdivision. Striatal striosomes (sometimes also referred
as striatal patches) are MSN, receiving dopaminergic input from
the SNc and glutamategic input from limbic cortical areas of layer
V. These striosomes form small clusters of neurons about 150–
300μm in diameter and are embedded in the so-called matrix.
Matrix neurons are projection neurons receiving input from the
occulomotor and sensorimotor cortex as well as input from the
thalamus. Besides the above mentioned neurochemical markers,
striatal patches are characterized by the presence of the μ-opiate
receptor 1 (μOR-1), whereas matrix neurons are characterized by
the presence of the calcium-binding protein Calbindin.
EMBRYONIC DEVELOPMENT OF THE STRIATUM
Ontogenetically, the striatum and the adjacent globus pallidus
originate from the same anlage that is located at the ventral por-
tion in each hemisphere of the developing telencephalon. This
anlage is called ganglionic eminence (WGE = whole ganglionic
eminence) and consists of three primordia which are referred
as lateral ganglionic eminence (LGE), medial ganglionic emi-
nence (MGE), and caudal ganglionic eminence (CGE). The WGE
appears at embryonic day E10.5 in rat fetuses and at about 42 days
post conception in the human fetus. The WGE is subdivided into
three functional areas: the upper layer that contacts the lateral
ventricle, is the so-called ventricular zone (VZ), the underlying
layer is referred as subventricular zone (SVZ) and contains pro-
liferating neural precursors. The central area where maturating
neurons are located is called mantle zone (MZ). The area between
MZ and SVZ is referred as intermediate zone (IZ).
PROLIFERATION AND CELL MIGRATION IN THE GANGLIONIC EMINENCE
Originating from a single central eminence that bulges into
each lateral ventricle, neuronal precursors start to proliferate
and migrate radially so that a second eminence appears lateral
to the first eminence at about E12.5 in the rat fetus. The first
appearing eminence will give rise to the MGE, while the second
one develops into the LGE. In the rostral region, the two emi-
nences are separated by a rostro-caudal furrow, but in the caudal
region, both eminences are fused and give rise the so-called CGE
(Hamasaki et al., 2003). The proliferation of SVZ precursors in
which the LGE is generated is referred as early phase of neuro-
genesis. The early phase of neurogenesis ends at about E14.5 in
the rat fetus. Subsequently, fibers extending from cerebral cortex
reach the newly generated striatal precursors, and thus generate
the corticostriatal pathway.
A second phase of neurogenesis can be observed between E17.5
and P2 in the rat fetus which is referred as late phase of stri-
atal neurogenesis. During that phase, proliferating precursors
migrate into the outer MZ toward the already existing neurons
generated during early neurogenesis that receive cortical input.
The early born striatal neurons are not equally separated by the
migrating late-born neurons; they rather remain grouped in cell
clusters (Krushel et al., 1995). Due to the incomplete separation
between early and late stage striatal neurons, a pattern appears
that can be observed until adulthood: the striosome and matrix
compartments. Striatal neurons located in the striosome were
generated during early neurogenesis, while neurons of the matrix
compartment were generated during late neurogenesis. Late-born
(matrix) striatal neurons receive cortical input independent and
different from the cortical input that early-born (striosomal)
striatal neurons receive. Thus, birth-dating results in a differ-
ent cortical innervation pattern and subsequently, in a different
functionality of striatal neurons.
GENETIC CONTROL OF STRIATAL DEVELOPMENT
The development of the striatum is strictly controlled by intrin-
sic and extrinsic molecular cues. Priming of ventral telencephalic
cells begins in the neural tube at about E9 in the rat fetus. Cells
located in the ventral neural tube receive Sonic hedgehog (Shh)
signals from the underlying prechordal plate and the ventral neu-
ral tube itself. While at the same time, cells of the anterior neural
tube receive the Wnt-antagonizing molecule Dickkopf-1 (Dkk-1)
as well as the fibroblast growth factor-8 (Fgf8), both secreted
by the anterior commissural plate. Downstream actors of Shh
are the homeobox proteins Gsx2 (also Gsh2) and Nkx2-1 (also
TTF-1) (Figure 1A). Nkx2-1 is expressed in the medial portion
of the ventral forebrain, whereas Gsx2 is expressed lateral to the
Nkx2-1 domain (Corbin et al., 2003). In the rat E10 fetal telen-
cephalon, both expression domains are separated, but Gsx2 and
Nkx2-1 expression domains overlap coincident with the appear-
ance of the GE. Besides the expression of these two homeodomain
proteins, Fgf8 and Shh pathway induce the expression of the fork-
head transcription factor Foxg1 (also referred as brain factor 1,
Bf1) at about E10 in the rat fetus (Shimamura and Rubenstein,
1997; Martynoga et al., 2005; Paek et al., 2009). Cells positive
for Foxg1 act autonomously during striatal development. Gsh2
induces the expression of Mash1 (also referred as Ascl-1) in the
ventral forebrain.
Mash1 is the mammalian homolog of the Drosophila
melanogaster neurogenic gene achate-scute. This is one key
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FIGURE 1 | Genetic control and cell migration in the ventral
telencephalon. (A) Gene regulatory network of striatal neurogenesis.
Secreted factors Fgf8 and Shh activate expression of early forebrain factors
Nkx2-1, Gsx2, and Foxg1. Gsx2 and Foxg1 regulate expression of Mash1,
which activates Dlx2 and suppresses astrocyte lineage via Hes5 and cortical
lineage via Pax6 and Ngn1/2. Mash1 and Dlx2 generate GABAergic projection
neurons in the ventral forebrain and Nkx2-1 is involved in interneuron
formation in the MGE. (B) Tangential cell migration in the fetal forebrain.
Schematic drawing of a coronal section of a rat E14 fetal forebrain (left
hemisphere). Light gray arrow indicates tangential cell migration of
acetylcholinergic precursors from the AEP/POA to the LGE. White arrows
indicate migration of GABAergic progenitors from the MGE to the LGE and
cortex. ACh: acetylcholine, AEP: anterior entopeduncular area, D1DR:
dopamine receptor D1, D2DR dopamine receptor D2, Gad1: glutamate
decarboxylase 1; GAT: GABA transporter, LGE: lateral ganglionic eminence,
MGE medial ganglionic eminence, POA: preoptic area.
transcriptional regulator of neuronal development, especially
in neuron vs. astrocyte fate decision. More specifically, Mash1
is expressed in brain regions supposed to adopt a GABAergic
phenotype. It plays an important role in the development of
ventral fore- and midbrain, as well as in the developing spinal
cord. The protein has a basic-helix-loop-helix DNA binding
motif and can interact with other proteins sharing the same
motif to conjointly bind the DNA. Besides inducting GABAergic
fates in the ventral forebrain, the second major role that Mash1
plays is to repress dorsal telencephalon-specific factors like Pax6,
Neurogenin1, and Neurogenin2. Besides Mash1, there is a second
key regulator in striatal neurogenesis: Dlx2. Foxg1 and Gsx2 have
been assumed to induce the expression of Dlx2 due to abnormal
expression in mutant embryos. Furthermore, is has been shown
thatMash1 directly regulates the expression of Dlx2 by interacting
with the Dlx2 enhancer (Poitras et al., 2007). Dlx2 is a mem-
ber of the distal-less gene family with six known members in the
mammalian genome, four of them (Dlx1,2,5,6) are involved in
striatal development. The homeodomain protein Dlx2 is specifi-
cally expressed in the LGE and MGE staring from E11 in the rat
fetus. Dlx2 has been associated with forebrain GABAergic specifi-
cation. Expression analysis of Dlx2 mutant embryos revealed that
Dlx2 regulates genes for GABA synthesis (Gad1) and transport
(GAT) as well as expression of dopamine receptors (Long et al.,
2009a,b). Furthermore, Dlx2 has been associated with matrix
neurogenesis, while, in turn, Mash1 has been associated with
generation of striosomal neurons. Therefore, it seems that the
striosome-matrix pattern is defined by birth dating and input
projections, as well as intrinsically. This idea is supported by work
that has published by Passante and co-workers who showed that
striatal patterning depends on direct cell-cell contract involving
ephrins and Eph receptors. Double knock-out of the ephrinA5
ligand and EphA4 receptor displayed aberrant striatal patterning
(Passante et al., 2008).
While striatal projection neurons are mainly generated in the
LGE, GABAergic interneurons are generated in the MGE and
cholinergic interneurons are generated in the medial located ante-
rior entopeduncular area (AEP), respectively, anterior preoptic
area (POA) form where they migrate to their target in the LGE
(Figure 1B) (Marin et al., 2000; Marín and Rubenstein, 2001). In
the MGE, not only striatal interneurons are generated, but also
cortical interneurons. Nkx2-1 that is expressed in the MGE until
E18 in the rat fetus plays an important role in striatal vs. corti-
cal interneuron sorting. Depending on the time point of Nkx2-1
down regulation cells either migrate toward the LGE or cortical
anlage (Nóbrega-Pereira et al., 2008).
Besides neurotransmitter release, areas projecting to the stria-
tum supply neurotrophins that are essential for survival of striatal
neurons. Dopaminergic cells from the SN secrete GDNF (glial
derived neurotrophic factor) which acts via the GDNF receptors
α1 and α2. Cortical terminals secrete BDNF (brain-derived neu-
rotrophic factor) which binds the TrkB receptor that is prevalently
expressed by striatal neurons of the indirect pathway. Aberrant
BDNF signaling due to mutations in the TrkB receptor or one
of the downstream effector molecules leads to selective loss of
striatal projection neurons (Baydyuk et al., 2011). In good agree-
ment with this observation,Huntingtin (htt)mutations have been
shown to alter TrkB-mediated cell growth and survival provid-
ing a principle cause for striatal atrophy in the diseased brain
(Zuccato et al., 2001).
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DIFFERENTIATING STEM CELLS INTO STRIATAL NEURONS
Several attempts have been made to generate striatal neurons
from pluripotent embryonic stem cells (ESC). In 2008, Aubry and
co-workers presented a three- step protocol for the induction of
striatal neurons (Aubry et al., 2008). Initially, human ESCs are
pre-differentiated into neuronal rosettes on MS5 mouse feeder
cells. In a second step, the ventral telencephalic phenotype is
induced by growth factor treatment including Dkk-1, Shh, and
BDNF. Finally, maturation of striatal neurons is achieved by com-
bined treatment of BDNF, valproic acid, and cAMP. Using this
protocol, the authors successfully differentiated striatal precur-
sors from pluripotent human ESC and showed that these cells
mature into functional striatal neurons. Furthermore, induced
pluripotent stem cells (iPS) derived from skin fibroblasts from
Huntington’s disease patients (HD-iPS) were successfully differ-
entiated into GABAergic neurons using a similar protocol. These
cells were also positive Calbindin and DARPP-32 (dopamine- and
cyclic AMP-regulated phosphoprotein, MW= 32 kDa) ensuring a
striatal phenotype (Zhang et al., 2010).
In 2010, Vierbuchen and colleagues proved the direct con-
version of skin fibroblasts into functional neurons (Vierbuchen
et al., 2010). Conversion of fibroblasts can be achieved by forced
overexpression of pro-neuronal genes including Mash1. These
so-called induced neurons (iN) display a general neuronal phe-
notype and are able to form synapses and fire action potentials.
More specifically, skin fibroblasts could be converted into mid-
brain dopaminergic neurons (Caiazzo et al., 2011; Pfisterer et al.,
2011). Those cells were generated by combined overexpression
of general pro-neuronal and midbrain-specific transcription fac-
tors. These results prove that induction of a specific neuronal
phenotype is generally possible. Although not realized yet, it is
very likely that the conversion of fibroblasts into striatal neurons
can be achieved in a similar way using general neuronal tran-
scription factors like Mash1 in combination with WGE-specific
factors. These results provide a promising approach for the treat-
ment of neurodegenerative diseases such as Parkinson’s disease
(PD) and HD.
PRECLINICAL NEURAL TRANSPLANTATION IN HD
ANIMAL MODELS OF HD
Animal models of human brain diseases are imperfect, but
important scientific tools helping to learn more about dis-
eases, their pathology, etiology, underlying neurobiological and
behavioral aspects. Furthermore, they can offer a platform
to develop therapeutic avenues that could be translated to
the clinic.
HD is a genetically inherited, autosomal dominant disease
caused by the expansion of the CAG repeats in exon 1 of the htt
gene (The Huntington’s Disease Collaborative Research Group,
1993). The disease severely affects numerous regions of the brain,
particularly the medium spiny striatal projection neurons, and
is associated with motoric and cognitive pathology (Ross and
Tabrizi, 2011). There are two categories of animal models avail-
able in pre-clinical HD research: genetically modified and lesion
models. Both of these approaches result in modeling various neu-
ropathological, metabolic, and behavioral symptoms of HD such
as dysfunction and degeneration of striatal neurons, and motoric
and cognitive deficits. Below is a summary of the models that are
relevant in the field of cell therapy, otherwise animals models for
HD have been extensively reviewed elsewhere (Cenci et al., 2002;
Ramaswamy et al., 2007).
Genetically modified models
The identification of the mutant htt gene has permitted the
establishment of a variety of genetically modified rodent models
(mainly in mice, but some in rats) including transgenic, knock-
in, knock-out, and virally inserted poly-glutamine tract models
(Wang and Qin, 2006; Heng et al., 2008). Genetically modified
models have a lot of face validity and authenticity as they are
constructed on the same rationale that lies behind the pathol-
ogy present in humans: the genetic mutation in the htt gene
that causes HD. These models are ideal for studying cellular and
molecular aspects of the disease (Crook and Housman, 2011).
However, there are significant differences between models of
genetically modified animals regarding the behavioral and cellu-
lar consequences of the expression of the mutant gene, the rate of
onset of the pathology, the distribution pattern of the inclusions,
the degree of neuronal death, and expected life span of the ani-
mals. For this reason, genetically modified models are typically
not used to study the viability of neural transplantation in HD:
issues concerning the restoration of GABAergic circuitry are tra-
ditionally addressed using lesion models as this allows for a more
precise control of when and where striatal projection neurons
should degenerate.
Excitotoxic lesion models
Over the years, twomain types of excitotoxic cell deaths have been
described: indirect and direct. Indirect, or secondary, excitotox-
icity is process by which cells are made vulnerable first which
then leads to excitotoxic neuronal death mediated by otherwise
sub-toxic glutamate. The mechanism implicated is metabolic or
oxidative stress and is dependent on a progressive impairment
of neuronal mitochondria-based energy metabolism (Beal, 1998).
Common agents that have been used to generate animalmodels of
HD by inducing secondary excitotoxicity are the metabolic toxins
malonate and 3-nitropropionic acid (Beal et al., 1993; Brouillet
et al., 1993; Henshaw et al., 1994; Roitberg et al., 2002). Direct, or
primary, excitotoxicity can be induced by excessive or prolonged
glutamate receptor activation. In animal models of HD, this is
done using stereotactic neurosurgery methods as only this way
can one induce acute neuronal loss in a highly precise and selec-
tive fashion in the rodent CNS using glutamate analogs such as
kainic, ibotenic, or quinolinic acids (Coyle and Schwarcz, 1976;
Schwarcz et al., 1979, 1980, 1983, 1984; Beal et al., 1991; Beal,
1992). The underlying mechanisms of glutamate receptor medi-
ated toxicity are complex but excessive calcium influx (Choi,
1987; Tymianski et al., 1993) is a major factor, and neuronal
death occurs via both necrotic and apoptotic pathways (Lau and
Tymianski, 2010).
Over the past decade, quinolinic acid has emerged as the
excitotoxin of choice in lesion models of HD due to the repro-
ducibility of cell loss, and its selectivity for striatal neurons. The
selectivity is explained by the toxin’s high affinity for the NMDA
receptors found on post-synaptic membranes of specific striatal
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neurons. Importantly, models using quinolinic acid lesions have
been shown to replicate the features of HDpathology well, includ-
ing the differential vulnerability of striatal neurons such as the
depletion of GABA and Substance P positive neurons, but sparing
of Somatostatin and Neuropeptide Y positive neuronal subpopu-
lations that typically co-localize with NADPH-diaphorase (Beal
et al., 1986, 1989). By carefully manipulating the lesion param-
eters such as the volume, dose, infusion rate, lesioning location,
and the number of lesion sites, the cellular and behavioral impact
of the toxin can be controlled. Quinolinic acid induced excito-
toxic lesions of the striatum are typically unilateral. This lesion
does not compromise the animal’s ability to feed and clean itself,
but produces consistent impairments in contralateral paw use,
or deficits in responding in the contralateral space. The unilat-
eral lesion model also permits the intact striatum to be used for
histological control.
CELL REPLACEMENT THERAPY IN ANIMAL MODELS OF HD
Cell replacement therapy as a clinical method for repairing dam-
age to the brain has grown out of the experimental work starting
over three decades ago. Originally, scientific interest looking into
transplantation date back to the work by Elizabeth Dunn in the
early part of the twentieth century, highlighted several principal
factors that are still recognized today to be critical in produc-
ing successful grafts, such as the age and identity of the donor
tissue and the method and the region of delivery of the graft.
After many decades of hiatus, studies into cell transplantation
were revived in the early 1970s when Olson and colleagues per-
formed intraocular grafts of neural tissue into animals. However,
the modern era of intracerebral transplantation started in the late
1970s by Stenevi, Björklund, and Svendgaard with their work
on catecholamine grafts into rodent forebrain (Stenevi et al.,
1976). Equally important, animal models of neurodegenerative
diseases started appearing in the 1970s: Ungerstedt developed
the 6-hydroxydopamine based striatal dopamine depleting lesion
as a rodent model for PD (Ungerstedt, 1971), whilst Coyle and
Schwarcz lesioned striatal projection neurons by injecting exci-
totoxins into the striatum as a way of simulating HD pathology
(Coyle and Schwarcz, 1976). Over the years, numerous additional
improvements have been made in the surgical, cell preparation,
and transplantation protocols of striatal cells grafted into the HD
model (Fricker et al., 1996, 1997a,b; Nikkhah et al., 2009; Jiang
et al., 2011).
Selecting the type of cells for transplantation is influenced by
multiple factors, including availability, safety, ethics, the dispo-
sition of the damage, and the level of repair that is required.
Whether or not a particular graft is able to reverse any func-
tional impairment will depend on the characteristics of the cell,
including its plastic properties. However, it must be a considera-
tion when thinking about the choice of cells in order to be able
to achieve maximum recovery from specific functional deficits.
Understanding the mechanisms of action of a graft in a par-
ticular environment promotes more effective and efficient cell
therapies. Importantly, even without any functional anatomical
reconnection, cells placed at a strategic site can still act as a
neurotransmitter, a neurotrophic factor, or as a neuroprotective
agent.
Today, the best source of graft tissue comes from dissected pri-
mary embryos since they contain the phenotypically appropriate
populations of neurons at the optimal stage of development for
growth and establishment of afferent and efferent connections.
However, there are major obstacles in the use of primary embry-
onic tissue for grafting in the clinic, including screening, storing,
quality control, and standardization of cells obtained separately
on each occasion, as well as the moral, ethical, and practical
concerns associated with collection of the products of elective
abortion. Increasing effort is, therefore, being put into investi-
gating the use of alternative cell sources (for example, embryonic
stem cells, neural stem cells, iPS) for cell replacement therapies
in various types of neurodegenerative disease, or CNS damage,
including HD. Examining the advantages and disadvantages of
the novel experimental cells is out of the scope of this review
and this has been done extensively elsewhere (Zietlow et al., 2008;
Dunnett and Rosser, 2011; Nicoleau et al., 2011). The following
section will look at the use of primary striatal embryonic tissue in
restoring anatomically and functional the GABAergic circuitry in
animal models of HD.
ASSESSMENT OF CELL THERAPY STRATEGIES IN ANIMAL
MODELS OF HD
How is it determined whether the experimental intervention has
been successful or not? In the case of preclinical cell-therapy
studies in the context of HD, as well as in other disease mod-
els such as Parkinson’ disease, there are typically two phases.
Firstly, the graft-mediated behavioral and functional effects are
assessed by testing the animals on various behavioral paradigms
focusing on motor and/or cognitive performance. Secondly, fol-
lowing the sacrifice of the animals, the brain is prepared for
thorough histological analysis that has as its objective the assess-
ment of the graft, including survival, phenotype, and possible
migration, afferent and efferent connections. Data generated
over time in preclinical transplantation studies in the HD
model show that primary rat embryonic striatal tissue (E13–
E15 WGE) can survive, anatomically integrate with the host
and confer functional benefits on simple motor, sensorimotor,
as well as on complex cognitive tasks (Brasted et al., 1999a,b;
Döbrössy and Dunnett, 2007). Experimental evidence strongly
suggests that the basis for the graft-mediated functional and
behavioral recovery is founded on two main factors: appro-
priate anatomical and functional integration of the graft with
the host.
Morphological and anatomical assessment
What happens to the embryonic striatal cells following graft-
ing into a lesioned striatum, what they become and how well
they integrate with the host is typically studied by various stain-
ing and image analysis protocols, but can also be approached
by in vivo push-pull perfusion or non-invasive imaging meth-
ods, for example. The morphology and its cellular composition of
the graft is an essential part of all investigations (Figures 2A–L).
Typically, E13–E15 WGE are used as the source of cells for
grafting as this tissue contains the progenitor cells that differ-
entiate into striatal projection neurons (mainly medium spiny
striatal neurons), as well as interneurons. However, at this stage
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FIGURE 2 | Unilateral striatal quinolinic acid lesion and fetal cell
transplantation. Photomicrographs illustrate sections from the control, the
lesion, and the graft. Groups were stained with a neuron specific stain
(NeuN; A, D, G), with a dopaminergic marker (tyrosine-hydroxylase; B, E, H),
or for striatal-like tissue (DARPP-32; C, F, I). (A–C) The controls show regular
staining without any deformation. (D–G) The enlarged ventricles, the necrotic
core, and the reduction of staining in the striatum are apparent on the
lesioned sections. (G–I) The grafted striatal tissue (∗ ) survived in the lesioned
striatum with striatal-like neurons aggregating into patches (H, I). Larger black
dots delineate lesioned vs. intact striatum interface; smaller black dots show
graft vs. host interface. (J–L) High magnification images of DARPP-32
positive cells from the P-zone of grafted animals. Arrows indicate individual
DARPP-32 positive grafted neurons. Histology was done 35 weeks
post-grafting. P, patch; NP, non-patch. Scale bar in I = 1mm; scale bar in L =
20μm. Str, striatum; CC, corpus callosum; LV, lateral ventricle; Ctx, cortex;
AC, anterior commissure. Adapted from Döbrössy and Dunnett (2005).
of the developing WGE, there are also progenitor cells for future
cortical and pallidal neurons, which explain the heterogeneous
composition of the grafts. The distinction between the striatal
and non-striatal populations is done by staining the grafts for
the presence of DARPP-32, which is used as a marker for the
striatal-like neurons in the graft. Graft areas staining positive for
DARPP-32 are known as P-zones (“P” for patch), whilst areas
remaining negative are referred as NP zones (“NP” for non-patch)
(Figures 2J–L). Various other markers can be used to visualize the
P-zones, including AChE (striatal interneurons), tyrosine hydrox-
ylase (TH, stains the dopaminergic inputs on the graft which are
exclusive found on the striatal-like part of the graft). P-zones
represent “islands” in otherwise NP-sections of the graft, and
that the striatal-like cells are not randomly scattered around in
the graft. This suggests that the striatal-like cells in the single-
cell suspension or after the transplantation, form clusters and
group together to establish zones of striatal-like cells excluding
the other neuronal types to result in the P and NP patterns
observed.
The striatal projection neurons are GABAergic, but a subset of
them also co-expresses Substance P, Enkephalin, and Calbindin.
The graft itself is commonly identified with NeuN staining which
labels up all the cells in the graft whether they are striatal
or not. NeuN and DARPP-32 staining permits analysis of sev-
eral crucial parameters associated with the graft and the lesion
model such as graft volume, DARPP-32 positive cells, the pro-
portion of P and NP-zones, etc. Anatomical integration and
the restoration of GABAergic circuitry is supported by diverse
evidence. Firstly, using antero- and retrograde tracingmethods, as
well as xenografts, it has been shown that the transplanted striatal
tissue sends efferent projections to the host globus pallidus, and—
under certain conditions—to the substantia nigra. Furthermore,
the striatal grafts can receive afferent projections from the cor-
tex, thalamus, substantia nigra, and the raphé nucleus (Wictorin
et al., 1992). Secondly, electron microscopy data shows that tha-
lamic and nigral inputs can make synaptic contacts with MSNs
within the grafts (Clarke and Dunnett, 1993). Thirdly, activa-
tion of host nigral inputs to striatal grafts can stimulate GABA
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release from striatopallidal terminals in the globus pallidus in the
grafted animal with the same temporal resolution as in the intact
striatopallidal neurons (Sirinathsinghji et al., 1988).
Functional and behavioral assessment
Grafted cells could survive and integrate anatomically with the
host neuronal circuitry, but without a functional impact on the
animals’ behavior, it would be difficult to argue for clinical trans-
lation. Functional impact of the cells can be measured by using a
wide range of behavioral tasks. The unilaterally lesioned striatum
into which the striatal grafts are placed receives input from
different cortical areas, including motor, sensorimotor, and asso-
ciative areas, and this is reflected in the diverse nature of deficits
observed following striatal lesions in the rat (McGeorge and Faull,
1989). For example, dorsolateral striatal lesions selectively pro-
duce skilled forelimb deficits, whilst dorsoventral striatal lesions
impair both skilled forelimb use and tongue reaching. Medial stri-
atal lesions, receiving inputs mainly from the auditory and visual
cortex, do not affect either measurement (Pisa, 1988; Whishaw
et al., 1987; Pisa and Cyr, 1990; Fricker et al., 1996). In a choice
reaction-time task, lateral and medial striatal lesions induce ipsi-
lateral response bias and increase latency in response initiation,
respectively (Brown and Robbins, 1989). Lesions of the antero-
medial area of the striatum, a region that receives its afferents
predominantly from associative, auditory, and visual cortices,
induces deficits in delayed alternation, and spatial navigation
tasks, for example, but leaves visual discrimination performance
intact; however, lateral, particularly ventrolateral striatal lesions,
destroying cortical afferents from sensorimotor areas, disrupt
performance on complex visual stimulus-response habit tasks
(Divac et al., 1978; Isacson et al., 1986).
Graft-associated functional recovery is typically assessed using
manual tests; recovery on more sophisticated behaviors involv-
ing rule learning or goal-directed actions are assessed by operant
behavior tasks needing more specialized equipment. There is a
vast amount of data that suggests that embryonic E13–E15 striatal
grafts can promote partial, or in some case complete, functional
recovery in simple motor tasks (Isacson et al., 1984; Sanberg et al.,
1986; Döbrössy and Dunnett, 1998, 2003), sensorimotor tasks
(Döbrössy and Dunnett, 2005, 2006b, 2007), motor skills tasks
(Döbrössy and Dunnett, 2005, 2006a; Dunnett et al., 1988), and
in cognitive, learning and memory tasks (Isacson et al., 1986;
Mayer et al., 1992; Döbrössy and Dunnett, 1998; Brasted et al.,
1999a,b).
OPTIMIZING TRANSPLANT-MEDIATED FUNCTIONAL RECOVERY
As discussed in the previous section, striatal GABAergic cells
when transplanted into the damaged striatum can survive and
integrate, and even reverse some functional deficits. However,
functional recovery is mostly partial, meaning that full recov-
ery of the animals’ capacity on more complex tasks is seldom.
Also, except for some of the simplest behavioral tasks, such as
drug-induced rotation, regaining some of the lost function fol-
lowing grafting can be time and training dependent. What are
the mechanisms behind graft-mediated functional improvement,
and what factors influence this process? Is it possible to positively
impact on the anatomical integration and functional recovery by
manipulating the grafted animals’ post-grafting experience, or
does graft-development follow a default pathway following trans-
plantation? These issues concern the “plasticity” of the graft: its
capacity to respond to the macro-environment by adapting its
cellular, molecular, or morphological properties that might lead
to improved functional brain repair. For example, recovering per-
formance on complex tasks requires the (re-) establishment of
afferent and efferent connections with the host brain which are
appropriate to the particular function that needs to be restored. In
addition, studies have shown that even circuit reconstruction may
not be sufficient for full functional recovery, but the anatomical
integration needs to be back-up by appropriate behavioral train-
ing that provides the opportunity for the animal to “relearn” the
lost function using the graft as the neural substrate (Coffey et al.,
1989; Mayer et al., 1992; Brasted et al., 1999a,b). Experimental
evidence has accumulated supporting the hypothesis that expe-
rience and training play an important part in the plasticity of,
and functional recovery provided by, neural grafts [for review
see (Döbrössy and Dunnett, 2001)]. More specifically, a series of
studies over the past few years were designed to shed light on
the conditions and factors that impact upon the development of
embryonic striatal tissue transplanted into a unilaterally lesion
rat model of HD. In particular, data from our group strongly
suggests that:
1. Experience prior to grafting can influence the cellular and mor-
phological features of the grafts, in particular that of the function-
ally important DARPP-32 positive striatal-like neurons within
the transplants. Data shows that a greater number of DARPP-
32 cells were present in the grafts of animals that received
intensive unilateral training prior to grafting on the ipsilateral
paw compared to those that were trained on the contralateral
paw; this suggests that training can have both a positive and
a negative effect and that timing and specificity plays a role
(Döbrössy and Dunnett, 2005).
2. The features of embryonic striatal grafts can be influenced follow-
ing transplantation by environmental complexity and training.
Three aspects associated with striatal plasticity were examined:
dendritic spine densities, cell volumes of the grafted neurons,
and changes in the levels of BDNF. Functional recovery was
seen in all grafted animals independent of the whether or not
they were exposed to the enriched environment. However, at
the level of morphological and cellular analysis, variations in
the graft development were apparent subsequent to the dif-
ferential housing and exercise regimes. Animals housed in the
enriched environment had significantly more BDNF, a candi-
date substrate for influencing graft morphology and plasticity,
and their grafts had both greater spine densities and larger cell
volumes. The study gave a strong indication that environmen-
tal complexity is a factor that affects the plasticity of grafted
cells in situ (Figures 3A–D) (Döbrössy and Dunnett, 2006b).
3. Both the duration of the exposure and the extent of differen-
tial housing can influence multiple parameters of grafted cell
morphology. The factors acted either independently, e.g., on
graft size, complementarily, e.g., on spine density, or had no
distinctive effect, e.g., on lesion size (Döbrössy and Dunnett,
2008).
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FIGURE 3 | Spine density and synaptic plasticity in grafted neurons.
(A–C) Photomicrographs and dendritic spine density of transfected (LacZ
lentivirus) grafted neurons. Sections were double-stained for ß-galactosidase
and DARPP-32 to identify specifically the dendrites of the striatal-like cells
within the grafts. (D) Spine density was calculated as the number of spines
per length of dendrite on DARPP-32 positive neurons within each transplant
from the different experimental conditions. ∗P < 0.05, comparing housing
and exercise regimes [Döbrössy and Dunnett (2006b)]. Scale bar in A and
C = 25μm; (E–H). The corticostriatal “in vitro“-graft preparation. (E)
Schematic representation of electrode positions within the striatal graft in
vitro slice preparation. (F) Photomicrograph demonstrating the endogenous
GFP fluorescence of the transplanted tissue within the striatum. CTX, cortex;
CC, corpus callosum; STR, striatum. (G–H) Extracellularly recorded synaptic
plasticity. (G) Expression of LTD in graft and control recordings. (H)
Expression of LTP in graft and control recordings. HFS, high-frequency
stimulation Mazzocchi-Jones et al. (2009).
4. A possible source of the diversity in graft-induced behavioral
recovery is individual differences between the experimental ani-
mals used. The data suggests that specific training of the paw
controlled by the grafted striatum can influence the degree of
graft-associated functional effect. The findings further demon-
strated that grafts have the capacity to influence behavior, and
importantly, the graft-effect was sensitive to experience and
training (Döbrössy and Dunnett, 2006a).
5. Embryonic striatal grafts form functional connections with the
host striatal circuitry, capable of restoring synaptic transmission
and bi-directional synaptic plasticity, as evidenced by long-term
potentiation and depression. Furthermore, environmental
enrichment can facilitate the expression of long-term poten-
tiation in the grafted striatum. Observing mechanisms of
plasticity in the transplants, which can be influenced by envi-
ronmental factors, suggests a high degree of physiological
and functional integration and interaction between the trans-
plant and the host. These results indicate that striatal grafts
express synaptic correlates of learning, and thereby provide
direct evidence of functional neuronal circuit repair, an essen-
tial component of “functional integration” (Figures 3E–H)
(Mazzocchi-Jones et al., 2005, 2009, 2011).
In summary, the studies show that the development, including
the morphological and cellular properties of embryonic striatal
transplants, can be influenced by experience and the environment
both prior and after transplantation into the host. The data sug-
gest that neurorehabilitation should be a feature of clinical trials
of cell transplantation in order to exploit the underlying mecha-
nisms that promote anatomical integration of the grafted cells and
maximize transplant-mediated functional recovery (Döbrössy
et al., 2010).
CLINICAL TRANSPLANTATION IN HD PATIENTS
The previous sections summarize the experimental data from
animal models of striatal degeneration and repair that served
as rationale for clinical translation of cell-based therapy in
HD: the functional and anatomical restoration of the dam-
age and cell loss through the replacement of the degenerating
cell by neuronal transplantation. Identifying optimal conditions
leading to transplant-associated functional recovery and anatom-
ical integration—producing appropriate spatial/temporal neuro-
transmitter release—is a key research target.
OPEN LABEL TRIALS
The first open label trials for clinical application of neuro-
transplantation in HD patients have been reported in the early
1990s, however, publications contained limited details on the
functional outcome and the methodology used (Sramka et al.,
1992; Madrazo et al., 1995). Results from a trial of bilateral
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stereotactic transplantation of isolated LGE tissue were reported
in 1998 (Kopyov et al., 1998). Transplants in this trial were
mechanically dissociated and derived from 5 to 8 foetuses of a
CRL of 20 to 32mm. Deposits were localized within the cau-
date nucleus and to a smaller extend within the putamen, but
the immunosuppressive regimen was not specified. Three patients
were assessed according to the core assessment program for
intracerebral transplantation in HD (CAPIT-HD). The investi-
gators reported limited improvements in motor functions, as
well as functional and behavioral improvements only in two
patients, all measured using the UHDRS. However, the follow
up period was only 12 months. Mechanically processed LGE-
transplantation was used again in another clinical trial (Hauser
et al., 2002). Immunosuppressive medication (Cyclosporin A)
was administered for six months, and the suspension was again
injected into the caudate and putamen. Clinical assessment was
performed according to the CAPIT-HD protocol. The authors
reported a slight clinical improvement in five of seven patients
in motor and cognitive functions, but severe intracranial haem-
orrhage was described as a side effect in three patients. Long-
term clinical data on the above mentioned trial was poorly
documented.
Pre-clinical data suggests that transplantation of tissue from
the WGE compared to LGE, provides better functional recov-
ery. Basing on these experiments, a series of clinical trials were
initiated using WGE tissue (Bachoud-Lévi et al., 2000; Rosser
et al., 2002). In an open-label trial, five moderately-affected HD
patients received human WGE tissue which was mechanically
processed. A triple immunosuppression regimen (Cyclosporin A,
Azathioprin, Prednisolon) was applied for more than 12 months
(Bachoud-Lévi et al., 2000). Four out of five patients experienced
improvement in cognitive and motor functions post-operatively
during the initial follow up period of the first clinical report
after two years. One patient worsened after cyst formation on
one grafting site. A follow-up report comprising the long term
clinical course six years after grafting described a slight wors-
ening in three patients, which was more dominant in motor
outcome than for cognitive improvement (Bachoud-Lévi et al.,
2006). PET-scanning showed increased frontal and striatal glu-
cose metabolism in three patients, which had an overall stable
clinical course. The slight worsening in the three patients dur-
ing the long-term clinical course was very limited, compared
to the non-responding patients, and the WGE transplant was
considered to modify the disease progression in a subgroup of
patients.
The British “NEST-UK” consortium used a slightly different
approach by transplanting cells derived from enzymatically disso-
ciated human WGE, resulting in a higher level of cell separation
at the time point of transplantation. From this study, a six-month
follow-up report has been published that does not reveal any
clinical changes at this early time-point (Rosser et al., 2002). A
recent report on long-term outcome and PET-findings after graft-
ing indicated stabilization and long-term improved metabolism
in one patient 10 years after grafting, but also continuing clini-
cal deterioration in a second patient who was transplanted with
the same method (Reuter et al., 2008; Bachoud-Lévi, 2009).
Ideally, data from a controlled trial would help in assessing the
effectiveness of the treatment. Currently, there is an on-going
clinical trial (MIG-HD trial) with a coordinating centre in Créteil,
France, and affiliations in other French cities, Belgium, Italy, and
Germany, and results of this trial are expected within the next 24
month. Similar efforts made for PD neurotransplantation already
resulted in new disease insights and a better transplantation pro-
tocol that is now translated into the clinics within the EU-funded
TRANSEURO network.
GRAFT HISTOLOGY
Published post mortem data from HD patients who died sev-
eral years after grafting are mostly derived from LGE transplants.
In a single case, a patient who participated in the pan-European
MIG-HD-trial died six months after bilateral WGE grafting, rep-
resenting the shortest time point after grafting so far. In this case,
markers for on-going graft maturation (e.g., mitotic marker Ki67,
neural stem cell marker Doublecortin, and Sox2) were detected
in the graft (Capetian et al., 2009) and Figure 4A). In addi-
tion, DARPP-32 positive striatal projection neurons were found
as well (Figure 4B). It could be shown that these grafted DARPP-
32 positive neurons are innervated by host-derived TH positive
dopaminergic fibers as indicated by co-localization between TH
and the synapse marker Synaptophysin (Figure 4B’, ∗).
Published post-mortem data from HD-patient who deceased
late after grafting is mostly originated from LGE transplants.
Eighteen (Freeman et al., 2000), 74 and 79 months after trans-
plantation (Keene et al., 2007), mature neuronal grafts expressing
typical striatal projection-neuron and interneuronal markers and
comprising typical striatal architecture of striosome and matrix
were detected. In the very long-term surviving patients, the clin-
ical deterioration might have been enhanced by perioperative
complications mostly related to surgery. Using an unorthodox co-
transplantation technique, combining grafting of a sural nerve
with LGE tissue of four donors, the identification of compress-
ing cyst formation and contralateral graft overgrowth has been
found in a single case report evaluating the long-term (121
months) consequences of grafting of an HD patient (Keene et al.,
2009). The authors found surviving neurons within the graft,
but no characteristic MSNs were detected. In order to mediate
the proposed therapeutic effect, appropriate graft connectivity
involving both afferent and efferent synaptic connectivity, need
to be assessed. Post-mortem data show that grafts in HD patients
can receive dopaminergic (Freeman et al., 2000) and cortical glu-
tamatergic (Cicchetti et al., 2009) input, but to date, there are no
hints for graft efferents into the host brain.
The majority of reports examining post mortem grafts
describe transplants which are spared from severe inflamma-
tory reaction, often in contrast to the degenerating host brain
(Capetian et al., 2011). A recent report has put forward con-
tradictory evidence suggesting the possibility of pathology in
the graft after examining post-mortem brains from three HD
patients 9–10.5 years after transplantation (Cicchetti et al., 2009).
Some graft-derived cells showed signs of neurodegeneration,
e.g., expression of the apoptotic marker Caspase-3, host-derived
inflammatory activation involving microglia and astrocytosis.
These findings could be explained by general disease-associated
neuroinflammation.
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FIGURE 4 | Proliferation and integration of fetal striatal cells grafted in
a HD brain. Photomicrographs illustrate human fetal WGE-derived graft in a
post-mortem brain from a Huntington’s disease patient six month
post-grafting. (A) A large portion of the graft consists of proliferative neural
precursor cells shown by co-immunohistochemical labeling of the mitotic
marker Ki67 (red), and the neural stem cells markers Doublecortin (green)
and Sox2 (blue). (B) The graft shows a striatal phenotype displayed by large
aggregates of DARPP-32 positive neurons. These aggregates are
surrounded by a dense network of dopaminergic TH positive fibers.
(B’) High magnification of a single graft-derived DARPP-32 positive neuron.
A host-derived TH positive dopaminergic fiber forms a synapse with the
grafted cell as shown by Synaptophysin co-labeling (∗ ). Dcx, Doublecortin;
Syp, Synaptophysin. Scale bar in B = 30μm, scale bar in B′ = 5μm.
Adopted from Capetian et al. (2009).
ARE CLINICAL TRIALS IN HD A SUCCESS?
During the last decade, several reports on functional outcome
and post-mortem data of grafted HD patients were published.
The functional outcome differs between trials. However, there
are encouraging reports of patients displaying an improvement
of cognitive and motor deficits. One major shortcoming at the
interpretation of functional outcome is the lack of systematic
assessment in the LGE-transplantation studies (Kopyov et al.,
1998; Hauser et al., 2002). Comprehensive follow-up reports from
the NEST-UK-cases, is still missing, and results from the ongo-
ing MIG-HD-trial will not be available before 2013. Moreover,
initial clinical reports described surgical complications in a sig-
nificant higher number than in previous transplantation trials
in PD (Wijeyekoon and Barker, 2011). On the other hand,
methods applied in different trials are only rarely standardized
between groups. In the past, tissue dissection methods varied
between WGE transplantation and isolated transplants of the
LGE. Tissue dissociation methods involved both mechanical and
enzymatically methods. While for PD grafts, immune response is
rarely discussed, the inflammatory host environment within the
HD brain provides an environment more prone to evoke acute
immune response, suggested by outcomes of acute graft rejec-
tion in an HD patient 14 month after grafting (Krystkowiak et al.,
2007). Therefore, the optimal immune suppression remains to be
determined.
Data from long-term-follow-up of PD patients after intrac-
erebral grafting suggest clinical improvement to be a long-term
effect which can takemore than 10 years (Lindvall and Björklund,
2011), while HD pathology might progress in symptomatic
patients, resulting in impaired graft-host-interaction and lack of
graft projections. This might have an impact on patient selection,
as it suggests implanting early stage patients with less inflamma-
tory activity. After completing ongoing clinical transplantation
programs, a critical reassessment of grafting techniques, patient
selection criteria, tissue handling, and preparation and post-
operative therapy including immunosuppression should come
to pass.
CONCLUSION
The mosaic pattern of the adult striatum relies on two distinct
anatomic characteristics: (1) the striosome and matrix subdi-
vision and (2) the direct and indirect projection. The strio-
some/matrix subdivision is a result of striatal ontogeny. Striatum
and globus pallidus originate from the WGE, a structure located
in the ventral portion of the foetal telencephalon. During devel-
opment, two waves of neurogenesis (early and late) can be
observed in the WGE. Striosomal neurons are generated during
the early neurogenesis between E12.5 and E14.5 in the rodent
brain. Matrix neurons are generated during late neurogenesis
which takes place between E17.5 and P2. In the adult brain,
striosome and matrix neurons can be distinguished according
to their neurochemical markers and cortical afferents. The sec-
ond, independent anatomic characteristic of the adult striatum
refers to the projection targets of striatal MSN. Two distinct types
of projections neurons have been described for the adult stria-
tum: direct and indirect projection neurons. Neurons of the direct
projection type project to the SNr and the GPi. They predomi-
nantly express dopamine-receptor type 1 as well as Substance P
and Dynorphin as co-transmitter. Neurons of this type are acti-
vated by the release of dopamine from the SNr. Neurons of the
indirect projection type also project to the SNr and GPi, but addi-
tionally project to the GPe. Neurons of the indirect projection
type express type 2 dopamine receptors which are inhibited once
dopamine is released from the SNr, and express Enkephalin as
co-transmitter.
Striatal degeneration is a key feature in HD. HD is an auto-
somal dominant inherited disease that is caused by a triplet
repeat expansion in the human htt gene. In the diseased brain,
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cognitive and motor functions are severely affected. Due to the
relatively selective loss of striatal MSN, HD has come into consid-
eration for cell therapeutic approaches. The concept behind this
therapy is the transplantation of striatal precursor cells (derived
from the foetal WGE) into the diseased striatum. Grafted pre-
cursors are thought to mature in the host brain and replace
degenerated striatal neurons. In pre-clinical HD research, differ-
ent animal models are established to study the pathology of the
disease. These animal models can be grouped into genetically
modified and lesion-induced models. Neural transplantation was
successfully tested in HD animal models. Graft histology proved
that transplanted precursor cells mature and integrate into the
host striatum. Furthermore, behavioral assessment showed that
grafted cells participate to the basal ganglia circuitry and enable
functional recovery.
These promising results justified clinical transplantation tri-
als on small groups of HD patients. The first open label trials
revealed a positive outcome in subgroups of patients. Thus, a
follow-up controlled clinical trial was initiated (MIG-HD trial).
Since the trial is still on-going, no data on functional recovery
are available. Post-mortem data suggest that the cells mature into
neurons and acquire a striatal phenotype. Furthermore, grafted
cells are innervated by host-derived cortical and nigral afferents.
In the future, refinement of cell preparation and standardiza-
tion of transplantation protocols might be necessary to increase
clinical benefit.
Future prospects might also focus on the generation of
striatal neurons from alternative cell sources. Many gene
functions and molecular interactions involved in striatal neu-
rogenesis were already elucidated. Based on that, embryonic
stem cells and iPS were successfully differentiated into stri-
atal neurons in vitro. Further investigations may involve
the direct reprogramming of somatic cells into striatal
neurons.
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